---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021527"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:15:31.134459+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aeglea Q3 net loss $18.2M; cash $75.2M; pegtarviliase interim data expected Q4 2022

## Summary
- Cash, equivalents and securities total $75.2M as of Sept 30, 2022; runway into Q4 2023.
- Net loss $18.2M vs $20.3M in Q3 2021; revenue $0.2M from Immedica license.
- Phase 1/2 pegtarviliase trial for Homocystinuria dosing cohort 3 at 1.35 mg/kg; interim data planned Q4 2022.
- MAA for pegzilarginase (Arginase 1 Deficiency) submitted by partner Immedica currently under EMA review.
- Corporate restructuring announced; Jim Kastenmayer appointed interim CEO; permanent CEO search underway.

## SEC filing metadata
- accession: 0000950170-22-021527
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/0000950170-22-021527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/agle-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021527
- JSON: https://secwatch.observer/filing/0000950170-22-021527.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021527.txt

## Key facts
- Earnings Releases
  Spyre Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.2 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $0.2 million
  - Result: reported results
  source text: securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023. Aeglea recognized development fee revenues of $0.2 million in the third quarter of 2022 as a result of its license and supply agreement with Immedica for the commercial rights to pegzilarginase in certain territories outside the U.S. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/0000950170-22-021527-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.